RetinaRounds™

30: RetinaRounds™ Podcast 30: Jay Duker, MD

58 min · 21. joulu 2025
jakson 30: RetinaRounds™ Podcast 30: Jay Duker, MD kansikuva

Kuvaus

Retina Rounds is excited to welcome a true leader in ophthalmology and a giant in retina: Dr. Jay Duker. Dr. Duker is one of the most accomplished figures in our field, having served as Chair of Ophthalmology at Tufts Medical Center, where he helped shape both clinical care and research for over two decades.  He’s now President and CEO of EyePoint Pharmaceuticals and, in today’s episode, we discuss his remarkable career journey, his transition from academia to biotech, and a fascinating deep dive into tyrosine kinase inhibitors, clinical trial development, and what it really takes to bring a new therapy from concept to regulatory approval.  * Retina Rounds has no financial or conflicts of interest in the content presented

Kommentit

0

Ole ensimmäinen kommentoija

Rekisteröidy nyt ja liity RetinaRounds™-yhteisöön!

Aloita nyt

3 kuukautta hintaan 7,99 €

Sitten 7,99 € / kuukausi · Peru milloin tahansa.

  • Podimon podcastit
  • 20 kuunteluaikaa / kuukausi
  • Lataa offline-käyttöön

Kaikki jaksot

31 jaksot

jakson 30: RetinaRounds™ Podcast 30: Jay Duker, MD kansikuva

30: RetinaRounds™ Podcast 30: Jay Duker, MD

Retina Rounds is excited to welcome a true leader in ophthalmology and a giant in retina: Dr. Jay Duker. Dr. Duker is one of the most accomplished figures in our field, having served as Chair of Ophthalmology at Tufts Medical Center, where he helped shape both clinical care and research for over two decades.  He’s now President and CEO of EyePoint Pharmaceuticals and, in today’s episode, we discuss his remarkable career journey, his transition from academia to biotech, and a fascinating deep dive into tyrosine kinase inhibitors, clinical trial development, and what it really takes to bring a new therapy from concept to regulatory approval.  * Retina Rounds has no financial or conflicts of interest in the content presented

21. joulu 202558 min